Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

A Howell, D DeFriend, J Robertson, R Blamey, P Walton

Research output: Contribution to journalArticlepeer-review

Abstract

We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.

Original languageEnglish
Pages (from-to)29-30
Number of pages2
JournalLancet (London, England)
Volume345
Issue number8941
Publication statusPublished - 7 Jan 1995

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Breast Neoplasms
  • Drug Tolerance
  • Estradiol
  • Estrogen Antagonists
  • Female
  • Humans
  • Injections, Intramuscular
  • Tamoxifen
  • Clinical Trial
  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer'. Together they form a unique fingerprint.

Cite this